JP2021515541A5 - - Google Patents
Info
- Publication number
- JP2021515541A5 JP2021515541A5 JP2020542228A JP2020542228A JP2021515541A5 JP 2021515541 A5 JP2021515541 A5 JP 2021515541A5 JP 2020542228 A JP2020542228 A JP 2020542228A JP 2020542228 A JP2020542228 A JP 2020542228A JP 2021515541 A5 JP2021515541 A5 JP 2021515541A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1803746.5A GB201803746D0 (en) | 2018-03-08 | 2018-03-08 | PD1 binding agents |
| GB1803746.5 | 2018-03-08 | ||
| GB1813405.6 | 2018-08-16 | ||
| GBGB1813405.6A GB201813405D0 (en) | 2018-03-08 | 2018-08-16 | PD1 binding agents |
| PCT/EP2019/055927 WO2019170898A1 (en) | 2018-03-08 | 2019-03-08 | Pd1 binding agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021515541A JP2021515541A (ja) | 2021-06-24 |
| JP2021515541A5 true JP2021515541A5 (enExample) | 2022-03-15 |
Family
ID=61972796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542228A Pending JP2021515541A (ja) | 2018-03-08 | 2019-03-08 | Ｐｄ１結合剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10858435B2 (enExample) |
| EP (1) | EP3762419A1 (enExample) |
| JP (1) | JP2021515541A (enExample) |
| CN (1) | CN111819199A (enExample) |
| AU (1) | AU2019229676A1 (enExample) |
| CA (1) | CA3092174A1 (enExample) |
| GB (2) | GB201803746D0 (enExample) |
| IL (1) | IL277135A (enExample) |
| SG (1) | SG11202008246VA (enExample) |
| WO (1) | WO2019170898A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
| CN110087680B (zh) | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
| EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES |
| EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| GB201803745D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
| GB201914747D0 (en) | 2019-10-11 | 2019-11-27 | Ultrahuman Eight Ltd | PD1 and vegfr2 dual-binding agents |
| WO2021076197A1 (en) * | 2019-10-15 | 2021-04-22 | Diverse Biotech, Inc. | Conjugate molecules |
| CA3181776A1 (en) | 2020-05-26 | 2021-12-02 | Boehringer Ingelheim International Gmbh | Anti-pd-1 antibodies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3530736A3 (en) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CR20160319A (es) * | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| MA43028B1 (fr) * | 2015-10-02 | 2021-09-30 | Hoffmann La Roche | Anticorps bispécifiques pour pd1 et tim3 |
| GB201803745D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
-
2018
- 2018-03-08 GB GBGB1803746.5A patent/GB201803746D0/en not_active Ceased
- 2018-08-16 GB GBGB1813405.6A patent/GB201813405D0/en not_active Ceased
-
2019
- 2019-03-08 JP JP2020542228A patent/JP2021515541A/ja active Pending
- 2019-03-08 CN CN201980017416.5A patent/CN111819199A/zh active Pending
- 2019-03-08 EP EP19710389.8A patent/EP3762419A1/en not_active Withdrawn
- 2019-03-08 CA CA3092174A patent/CA3092174A1/en active Pending
- 2019-03-08 SG SG11202008246VA patent/SG11202008246VA/en unknown
- 2019-03-08 WO PCT/EP2019/055927 patent/WO2019170898A1/en not_active Ceased
- 2019-03-08 AU AU2019229676A patent/AU2019229676A1/en not_active Abandoned
-
2020
- 2020-06-25 US US16/912,023 patent/US10858435B2/en not_active Expired - Fee Related
- 2020-09-03 IL IL277135A patent/IL277135A/en unknown
- 2020-11-19 US US16/952,678 patent/US20210101981A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519100A5 (enExample) | ||
| JP2021515542A5 (enExample) | ||
| JP2021513323A5 (enExample) | ||
| JP2024513921A5 (enExample) | ||
| JP2022553908A5 (enExample) | ||
| JP7734753B2 (ja) | 抗ｃｌｄｎ６抗体およびその使用 | |
| FI4041763T3 (fi) | Pd1:tä ja vegfr2:ta kaksoissitovia aineita | |
| JP2021516537A5 (enExample) | ||
| JP2019201643A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| JP2017149720A5 (enExample) | ||
| RU2017145150A (ru) | Антитело против pdl-1, его фармацевтическая композиция и применение | |
| HRP20200583T1 (hr) | Protutijela koja neutraliziraju gp120 i njihova upotreba | |
| JP2018522541A5 (enExample) | ||
| JP2018506961A5 (enExample) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2021515544A5 (enExample) | ||
| JP2022533538A5 (enExample) | ||
| JP2021534797A5 (enExample) | ||
| JP2024540148A5 (enExample) | ||
| JP2020513759A5 (enExample) | ||
| JP2023542209A5 (enExample) | ||
| JP2021514654A5 (enExample) | ||
| JP2022517216A5 (enExample) | ||
| JP2025517737A5 (enExample) |